The vaccine is being searched all over the world to protect against this virus amidst increasing cases of Coronavirus. Now Britain has achieved great success in this. The vaccine that Oxford University has prepared has proved positive. In fact, the vaccine trial conducted by Oxford University has proved to be safe and there are indications that the immune system will be better. Its data will be published soon.
Results of phase 1/2 Oxford Covid-19 Vaccine trial published. Editor in Chief of UK based medical Journal ‘The Lancet’ says it is “safe, well-tolerated and immunogenic.” pic.twitter.com/8SyI97Dqgb
— ANI (@ANI) July 20, 2020
However, only two-phase results have been declared. The results of the Phase III trial have not been announced yet. It is believed that it will be announced soon.
What did the trial reveal
Oxford University tried the vaccine at 1,077 people. Experiments on these people have revealed that the injection of vaccines has produced antibodies in the body of these people. This success of Oxford University raises a lot of hope. In research published on Monday in the journal ‘Lancet’, scientists said they found that their experimental Covid-19 vaccine caused a double immune response in people between 18 and 55 years of age.
“We are seeing a good immune response in almost everyone,” said Dr. Adrian Hill, director of the Jenner Institute at the University of Oxford. “This vaccine would have particularly strengthened both sides of the immune system Hill said that the atoms produced by neutralizing antibodies are important to prevent infection. In addition, this vaccine causes a reaction in the body’s T-cells that help fight the coronavirus. He said that large trials evaluating the vaccine’s effectiveness included about 10,000 people from the UK as well as participants from South Africa and Brazil. These trials are still going on in a big way. Another big trial is going to start in the US soon, which is targeted to include around 30,000 people.
How quickly scientists are able to determine the effectiveness of a vaccine will largely depend on how much testing there does, but Hill speculates that they may have enough data by the end of the year to make sure Whether the vaccine should be adopted for mass vaccination campaigns. Hill said the Oxford vaccine was designed to reduce the spread of the disease and its spread. Hill said Oxford has partnered with drug manufacturer AstraZeneca to produce its vaccines globally and the company has already committed to producing two billion doses.